

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**愛 帝 宮 母 嬰 健 康 股 份 有 限 公 司**  
**AIDIGONG MATERNAL & CHILD HEALTH LIMITED**

*(Incorporated in Bermuda with limited liability)*

**(Stock code: 286)**

**PROFIT WARNING**

This announcement is made by Aidigong Maternal & Child Health Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on the Group’s preliminary assessment of its unaudited consolidated management accounts for the six months ended 30 June 2024 (the “**Period**”) and the information currently available to the Board, the Group expects to record a loss of approximately HK\$39.00 million for the Period, representing an increase in loss of HK\$16.07 million or 70.08% as compared to that in 2023.

The increase in the Group’s loss for the Period was mainly attributable to, among other things, (i) a decrease in revenue due to the depreciation of the exchange rate of RMB against Hong Kong dollars; (ii) the adverse macroeconomic impact, which customers were more cautious in spending, resulting in a decrease in the Group’s revenue during the Period; and (iii) the loss attributable to the newly opened postpartum care centres which are still in the early stage of opening and in the process of growing, thus eroding the profits of other existing centres and affecting the overall profits.

Notwithstanding the increase in the expected loss of the Group for the Period, the Board considers that the overall operating and financial position of the Group remains healthy and stable, and the Company will continue to strive to create value for shareholders in a long-term and sustainable manner. With the implementation of the Group's strategy of seizing quality markets, the Board has full confidence in the Group's business development and prospects.

The information contained in this announcement is only based on the preliminary assessment made by the Board of the information currently available to the Company, including the management accounts of the Group, which have not been reviewed by the audit committee of the Company and have not been reviewed or audited by the independent auditors of the Company and is therefore subject to change. Further details of the Group's financial performance will be disclosed when the Company's financial results for the Period are finalised and announced, which are currently expected to be published on 30 August 2024.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Aidigong Maternal & Child Health Limited**  
**Wang Aier**  
*Chairman*

Hong Kong, 26 August 2024

*As at the date of this announcement, the Board comprises Ms. Wang Aier, Mr. Lin Jiang, Mr. Li Runping and Ms. Meng Lijia as executive Directors; Mr. Lee Kar Lung as non-executive Director; and Mr. Lam Chi Wing, Mr. Wong Yiu Kit, Ernest and Mr. Shan Guoxin as independent non-executive Directors.*